Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term administration & dosage. Found 208 abstracts

no pagination
Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Apr;67(4):945-54.   PMCID: PMC3026871
Moral R, Santucci-Pereira J, Wang R, Russo IH, Lamartiniere CA, Russo J. In utero exposure to butyl benzyl phthalate induces modifications in the morphology and the gene expression profile of the mammary gland: an experimental study in rats. Environ Health. 2011 Jan;10(1):5.   PMCID: PMC3033239
Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clinical Cancer Research. 2010 Mar 15;16(6):1904-14.   PMCID: NIHMS352308
Patel RR, Sengupta S, Kim HR, Klein-Szanto AJ, Pyle JR, Zhu F, Li T, Ross EA, Oseni S, Fargnoli J, Jordan VC. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur J Cancer. 2010 Jun;46(9):1537-53.   PMCID: PMC2927957
Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008 May;19(5):977-83.
Held-Warmkessel J. Targeted cancer. These "smart weapons" hit cancer in novel ways. Nursing. 2008 Sep;38(9):26-32.
Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008 May 20;26(15):2497-504.
Huang CH, Millenson MM, Sherman EJ, Borghaei H, Mintzer DM, Cohen RB, Staddon AP, Seldomridge J, Treat OJ, Tuttle H, Ruth KJ, Langer CJ. Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy. J Thorac Oncol. 2008 Sep;3(9):1032-8.
Konski A, Garcia M, John M, Krieg R, Pinover W, Myerson R, Willett C. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys. 2008 Sep;72(1):114-8.   PMCID: PMC2570743
Langer CJ. Resectable non-small cell lung cancer in the elderly: is there a role for adjuvant treatment?. Drugs Aging. 2008 Jan;25(3):209-18.
Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Lesniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun;3(6):623-30.
Morgan MA, Darcy KM, Rose PG, DeGeest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ, Gynecologic Oncology G. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol. 2008 Sep;110(3):329-35.   PMCID: PMC2577579
Sarna L, Swann S, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Byhardt R, Wasserman T, Movsas B. Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. Int J Radiat Oncol Biol Phys. 2008 Dec;72(5):1378-84.
Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008 Feb 20;26(6):942-7.
Swaby RF, Jordan VC. Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin Breast Cancer. 2008 Apr;8(2):124-33.
Tseng M, Olufade T, Kurzer MS, Wahala K, Fang CY, van der Schouw YT, Daly MB. Food frequency questionnaires and overnight urines are valid indicators of daidzein and genistein intake in U.S. women relative to multiple 24-h urine samples. Nutrition and cancer. 2008 Jan;60(5):619-26.
von Mehren M, Schilder RJ, Cheng JD, Temmer E, Cardoso TM, Renshaw FG, Bayever E, Zannikos P, Yuan Z, Cohen RB. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol. 2008 Oct;19(10):1802-9.   PMCID: PMC2598415
Ma GX, Fang CY, Shive SE, Toubbeh J, Tan Y, Siu P. Risk perceptions and barriers to Hepatitis B screening and vaccination among Vietnamese immigrants. Journal of immigrant and minority health. 2007 Jul;9(3):213-20.
von Gegerfelt AS, Rosati M, Alicea C, Valentin A, Roth P, Bear J, Franchini G, Albert PS, Bischofberger N, Boyer JD, Weiner DB, Markham P, Israel ZR, Eldridge JH, Pavlakis GN, Felber BK. Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. Journal of Virology. 2007 Feb;81(4):1972-9.   PMCID: 1797580
Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006 Sep 10;24(26):4324-32.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term administration & dosage

administration & dosage Female therapeutic use Aged Middle Aged drug therapy Adult Male 80 and over Aged pathology adverse effects Antineoplastic Combined Chemotherapy Protocols Neoplasm Staging effects adverse Treatment Outcome metabolism therapy mortality Carboplatin pharmacokinetics Non-Small-Cell Lung Carcinoma chemically induced Antineoplastic Agents Drug Dose-Response Relationship analogs & derivatives Survival Rate Lung Neoplasms radiotherapy Paclitaxel Combined Modality Therapy Breast Neoplasms antagonists & inhibitors Disease-Free Survival Drug Administration Schedule Survival Analysis Neoplasms Monoclonal Antibodies Deoxycytidine derivatives drug Biological Tumor Markers Ovarian Neoplasms Salvage Therapy Prognosis Neoplasm Drug Resistance Taxoids United States erbB-2 Receptor immunology Polyglutamic Acid Drug Interactions Follow-Up Studies psychology blood Adjuvant Chemotherapy Quality of Life surgery analogs & physiology Sexual Behavior Protein-Tyrosine Kinases Stomatitis education Simian Acquired Immunodeficiency Syndrome Anus Neoplasms Biological Markers Hemorrhage Radiation Injuries Angiogenesis Inhibitors Radiation-Protective Agents Nitriles Tetrahydroisoquinolines Colostomy Maximum Tolerated Dose nursing Health Behavior Socioeconomic Factors Drug Eruptions Dimerization Age Factors epidemiology Vascular Endothelial Growth Factor A Phthalic Acids Reproducibility of Results Gene Expression Profiling Isoflavones CA-19-9 Antigen Estrogen Replacement Therapy Fetus Rats Amifostine Questionnaires toxicity Drug Delivery Systems Postmenopause Local Neoplasm Recurrence Fallopian Tube Neoplasms Vaccination Aurora Kinases Weight Loss Clinical Trials as Topic Intramuscular Injections use Immunohistochemistry Half-Life Circadian Rhythm veterinary Paronychia Animal Mammary Glands Pancreatic Neoplasms Cross-Sectional Studies Peripheral Nervous System Diseases Prostatic Neoplasms Young Adult Nude Mice Protocols Pyrroles Viral Load Progesterone Receptors Disorders of Excessive Somnolence Sprague-Dawley Rats Reverse Transcriptase Polymerase Chain Reaction Enzyme-Linked Immunosorbent Assay genetics Prospective Studies etiology Patient Education as Topic Preclinical Drug Evaluation drug effects therapeutic Feasibility Studies Immunization Programs Epidermal Growth Factor Receptor methods physiopathology Neoplastic Gene Expression Regulation Vietnam Adenocarcinoma Oral Administration Double-Blind Method statistics & numerical data SAIDS Vaccines Antineoplastic Antibiotics Retrospective Studies Antineoplastic Antimetabolites Quinazolines Soy Foods Heterologous Transplantation Fluorouracil
Last updated on Saturday, August 08, 2020